- Home
- TMCR vs ARVN Comparison
TMCR vs ARVN Comparison
Compare TMCR & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMCR | ARVN |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.0M | 516.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | TMCR | ARVN |
|---|---|---|
| Price | $6.20 | $8.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $15.05 |
| AVG Volume (30 Days) | 61.2K | ★ 552.1K |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.14 | $6.06 |
| 52 Week High | $8.75 | $14.22 |
Technical Indicators
Market Signals| Indicator | TMCR | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 48.76 |
| Support Level | $5.35 | $7.90 |
| Resistance Level | $6.57 | $8.90 |
| Average True Range (ATR) | 0.57 | 0.29 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 65.84 | 36.81 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.